Removing the whole breast, either for cancer or preventively in BRCA1/2 carriers, where bilateral risk-reducing mastectomy cuts breast cancer risk by 90% or more. For most early cancers, lumpectomy plus radiotherapy works as well, so mastectomy is chosen for large or multicentric tumours, inflammatory cancer, or patient preference.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
Total mastectomy removes breast tissue; modified radical adds axillary nodes; skin- and nipple-sparing variants allow immediate reconstruction with implants or the patient's own tissue. For most early cancers, lumpectomy plus radiotherapy gives identical survival (NSABP B-06, Milan trials), so mastectomy is chosen for large or multicentric tumours, inflammatory cancer, or patient preference. Bilateral risk-reducing mastectomy cuts breast cancer risk by 90% or more in BRCA1/2 carriers.
In plain words · DNA repair genes. Inheriting a broken copy raises breast and ovarian cancer risk, but tumours that lose them become uniquely vulnerable to PARP inhibitors and platinum.
Showing the target this term concerns: BRCA1 / BRCA2 (HRD).
Shares Lobular carcinoma in situ (LCIS), Invasive lobular carcinoma of the breast, Sentinel node biopsy, Ductal carcinoma in situ (DCIS).
Shares Lobular carcinoma in situ (LCIS), Paget disease of the nipple, Inflammatory breast cancer, Ductal carcinoma in situ (DCIS).
Shares NSABP B-06, Radiotherapy after mastectomy, Lumpectomy (breast-conserving surgery), HER2-positive breast cancer.
Shares BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, High-risk early HR-positive breast cancer, Male breast cancer.
Shares Lobular carcinoma in situ (LCIS), Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, HER2-positive breast cancer.
Shares Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy), BRCA-associated triple-negative breast cancer, BRCA1 / BRCA2 (HRD), Early triple-negative breast cancer.
Shares SUPREMO (BIG 2-04), Radiotherapy after mastectomy, Paget disease of the nipple, High-risk early HR-positive breast cancer.
Shares Adenoid cystic carcinoma of the breast, Secretory carcinoma of the breast, Metaplastic breast carcinoma, Paget disease of the nipple.